MDT

97.79

-1.28%↓

A

141.24

-3.25%↓

VEEV

221.27

+0.94%↑

HQY

86.08

-3.24%↓

NEOG

9.23

-2.43%↓

MDT

97.79

-1.28%↓

A

141.24

-3.25%↓

VEEV

221.27

+0.94%↑

HQY

86.08

-3.24%↓

NEOG

9.23

-2.43%↓

MDT

97.79

-1.28%↓

A

141.24

-3.25%↓

VEEV

221.27

+0.94%↑

HQY

86.08

-3.24%↓

NEOG

9.23

-2.43%↓

MDT

97.79

-1.28%↓

A

141.24

-3.25%↓

VEEV

221.27

+0.94%↑

HQY

86.08

-3.24%↓

NEOG

9.23

-2.43%↓

MDT

97.79

-1.28%↓

A

141.24

-3.25%↓

VEEV

221.27

+0.94%↑

HQY

86.08

-3.24%↓

NEOG

9.23

-2.43%↓

Search

Simulations Plus Inc

Atvērts

SektorsVeselības aprūpe

20.27 -0.83

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

19.89

Max

20.48

Galvenie mērījumi

By Trading Economics

Ienākumi

1.4M

676K

Pārdošana

961K

18M

P/E

Sektora vidējais

48.528

90.831

EPS

-0.034

Dividenžu ienesīgums

0.48

Peļņas marža

3.67

Darbinieki

212

EBITDA

-3M

2.3M

Rekomendācijas

By TipRanks

Rekomendācijas

Pirkt

Prognoze 12 mēnešiem

-4.47% downside

Dividendes

By Dow Jones

Dividenžu ienesīgums

Sektora vidējais

0.48%

2.20%

Nākamie ieņēmumi

2026. g. 2. apr.

Tirgus statistika

By TradingEconomics

Tirgus kapitalizācija

13M

381M

Iepriekšējā atvēršanas cena

21.1

Iepriekšējā slēgšanas cena

20.27

Ziņu noskaņojums

By Acuity

50%

50%

161 / 361 Rangs Healthcare

Simulations Plus Inc Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2026. g. 15. janv. 18:44 UTC

Galvenie tirgus virzītāji

Agenus Falls After $141 Million Zydus Deal Closes

2026. g. 15. janv. 17:51 UTC

Galvenie tirgus virzītāji

Galaxy Digital Climbs on Texas Data-Center Expansion Approval, Tokenized CLO Issuance

2026. g. 15. janv. 17:25 UTC

Galvenie tirgus virzītāji

ASML Exceeds $500 Billion in Market Value on TSMC's Blockbuster Spending Plans -- Update

2026. g. 15. janv. 23:48 UTC

Tirgus saruna

Global Forex and Fixed Income Roundup: Market Talk

2026. g. 15. janv. 23:48 UTC

Tirgus saruna

Nikkei May Decline as Enthusiasm Over Election Eases -- Market Talk

2026. g. 15. janv. 23:40 UTC

Tirgus saruna

Gold Edges Lower Amid Abating Geopolitical Risks -- Market Talk

2026. g. 15. janv. 23:11 UTC

Tirgus saruna

Global Equities Roundup: Market Talk

2026. g. 15. janv. 23:11 UTC

Tirgus saruna

Ryman Healthcare's Resales Remain Key Concern -- Market Talk

2026. g. 15. janv. 23:01 UTC

Tirgus saruna

New Zealand's Economy Enters An Upswing -- Market Talk

2026. g. 15. janv. 22:56 UTC

Tirgus saruna
Peļņas

Catalyst Metals Delivers a Beat With Record Gold Output -- Market Talk

2026. g. 15. janv. 22:51 UTC

Tirgus saruna

James Hardie's Plant Closures Could Boost Profit by 2%-3% -- Market Talk

2026. g. 15. janv. 22:19 UTC

Iegādes, apvienošanās, pārņemšana

Verizon Gets Final California Approval to Secure $9.6 Billion Frontier Deal -- WSJ

2026. g. 15. janv. 21:50 UTC

Tirgus saruna
Peļņas

Financial Services Roundup: Market Talk

2026. g. 15. janv. 21:50 UTC

Tirgus saruna
Iegādes, apvienošanās, pārņemšana

Energy & Utilities Roundup: Market Talk

2026. g. 15. janv. 21:50 UTC

Tirgus saruna

Basic Materials Roundup: Market Talk

2026. g. 15. janv. 21:27 UTC

Peļņas

BlackRock Caps 2025 With Record $14 Trillion in Assets -- 3rd Update

2026. g. 15. janv. 21:15 UTC

Tirgus saruna
Iegādes, apvienošanās, pārņemšana

Global Commodities Roundup: Market Talk

2026. g. 15. janv. 21:11 UTC

Tirgus saruna
Iegādes, apvienošanās, pārņemšana

Global Equities Roundup: Market Talk

2026. g. 15. janv. 21:11 UTC

Tirgus saruna
Iegādes, apvienošanās, pārņemšana

Canada Antitrust Watchdog Confirms Review of Canadian Energy Deal -- Market Talk

2026. g. 15. janv. 20:10 UTC

Tirgus saruna

U.S. Natural Gas Futures Settle Mixed -- Market Talk

2026. g. 15. janv. 20:04 UTC

Peļņas

These Stocks Are Today's Movers: TSMC, ASML, Goldman, Morgan Stanley, BlackRock, Coinbase, Sandisk, and More -- Barrons.com

2026. g. 15. janv. 20:03 UTC

Tirgus saruna

Oil Futures Fall As Iran Risk Premium Fades -- Market Talk

2026. g. 15. janv. 19:26 UTC

Tirgus saruna

Silver Closes at Fresh High -- Market Talk

2026. g. 15. janv. 18:29 UTC

Galvenie tirgus virzītāji

Agenus Falls After $141M Zydus Deal Closes

2026. g. 15. janv. 18:20 UTC

Peļņas

Wall Street Powers Nation's Biggest Banks to Record Year -- WSJ

2026. g. 15. janv. 17:56 UTC

Tirgus saruna
Peļņas

U.S. Bank Results Look Encouraging for European Peers -- Market Talk

2026. g. 15. janv. 17:20 UTC

Tirgus saruna
Iegādes, apvienošanās, pārņemšana

Auto & Transport Roundup: Market Talk

2026. g. 15. janv. 17:20 UTC

Tirgus saruna

Health Care Roundup: Market Talk

2026. g. 15. janv. 17:15 UTC

Tirgus saruna

Global Commodities Roundup: Market Talk

2026. g. 15. janv. 17:02 UTC

Iegādes, apvienošanās, pārņemšana

KBC Group Completes Acquisition of 98.45% Stake in 365.bank From J&T Finance Group

Salīdzinājums

Cenas izmaiņa

Simulations Plus Inc Prognoze

Cenas mērķis

By TipRanks

-4.47% uz leju

Prognoze 12 mēnešiem

Vidējais 19 USD  -4.47%

Augstākais 19 USD

Zemākais 19 USD

Pamatojoties uz 5 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi Simulations Plus Inc — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Pirkt

5 ratings

2

Pirkt

3

Turēt

0

Pārdot

Noskaņojums

By Acuity

161 / 361 Rangs Veselības aprūpe

Ziņu noskaņojums

Neutral

Volatilitāte

Zem vidējā

Ziņu apjoms (RCV)

Zem vidējā

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

$

Par Simulations Plus Inc

Simulations Plus, Inc. develops drug discovery and development software for modeling and simulation, and prediction of molecular properties utilizing artificial intelligence and machine learning based technology worldwide. The company operates through Software and Services segments. It also offers GastroPlus, which simulates the absorption and drug interaction of compounds administered to humans and animals; and DDDPlus and MembranePlus simulation products. In addition, the company provides products based on mechanistic and mathematical models, such as DILIsym, NAFLDsym, ILDsym, IPFsym, RENAsym, MITOsym, and OBESITYsym products. Further, it offers Absorption, Distribution, Metabolism, Excretion, and Toxicity Predictor for chemistry-based computer program that takes molecular structures as inputs and predicts their properties; and MedChem Designer, as well as MonolixSuite products for modeling and simulation that allows for population analyses, rapid clinical trial data analyses, and regulatory submissions. Additionally, the company provides clinical-pharmacology-based consulting services, which includes population pharmacokinetic and pharmacodynamic modeling, exposure-response analyses, clinical trial simulations, data programming, and technical writing services in support of regulatory submissions; and early drug discovery services. Furthermore, it offers creative and insightful consulting services to support its quantitative systems pharmacology and other modeling systems. The company serves pharmaceutical, biotechnology, agrochemical, cosmetics, and food industry companies, as well as academic and regulatory agencies. Simulations Plus, Inc. was incorporated in 1996 and is headquartered in Lancaster, California.
help-icon Live chat